专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08628956B2 Expression vector suitable for expression of a coding sequence for gene therapy 有权
标题翻译：适用于表达基因治疗编码序列的表达载体
公开(公告)号：US08628956B2
公开(公告)日：2014-01-14
申请号：US13423474
申请日：2012-03-19
申请人： Daekyung Koh , Kyuhyun Lee , Hyeon Lee , Seongtae Yun , Eui-Cheol Jo
发明人： Daekyung Koh , Kyuhyun Lee , Hyeon Lee , Seongtae Yun , Eui-Cheol Jo
IPC分类号： C12N15/63 , C12N15/113 , C07H21/04
CPC分类号： C12N15/63
摘要： Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
摘要翻译：提供了具有转录调节元件的新组合的基因治疗的表达载体，其包括启动子，增强子，内含子，非翻译区（UTR）和基因座控制区（LCR）。表达载体能够持续表达肝组织特异性基因，因此可有效用于治疗血栓形成，血友病，肝癌等。

12. 发明申请

US20120282686A1 EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY 有权
标题翻译：用于表达基因治疗编码序列的表达载体
公开(公告)号：US20120282686A1
公开(公告)日：2012-11-08
申请号：US13423559
申请日：2012-03-19
申请人： Daekyung KOH , Kyuhyun LEE , Hyeon LEE , Seongtae YUN , Eui-Cheol JO
发明人： Daekyung KOH , Kyuhyun LEE , Hyeon LEE , Seongtae YUN , Eui-Cheol JO
IPC分类号： C12N15/63 , C12N15/113
CPC分类号： C12N15/63
摘要： Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
摘要翻译：提供了具有转录调节元件的新组合的基因治疗的表达载体，其包括启动子，增强子，内含子，非翻译区（UTR）和基因座控制区（LCR）。表达载体能够持续表达肝组织特异性基因，因此可有效用于治疗血栓形成，血友病，肝癌等。

13. 发明申请

US20110129872A1 METHOD FOR A PRODUCTION OF A RECOMBINANT PROTEIN USING YEAST CO-EXPRESSION SYSTEM 审中-公开
标题翻译：使用YEAST共表达系统生产重组蛋白的方法
公开(公告)号：US20110129872A1
公开(公告)日：2011-06-02
申请号：US12628767
申请日：2009-12-01
申请人： Hyung Kwon LIM , Jin-Ho SEO , Yong-Cheol PARK
发明人： Hyung Kwon LIM , Jin-Ho SEO , Yong-Cheol PARK
IPC分类号： C12P21/06
CPC分类号： C12N9/90 , C07K2319/02 , C12N9/60 , C12N15/81
摘要： The present invention relates to a method for mass production of a recombinant protein comprising the step of culturing a yeast transformed with: a recombinant gene construct comprising a yeast promoter, a gene coding a signal sequence and a gene coding a target protein; and also with one or more genes coding folding accessory protein selected from the group consisting of PDI1 (protein disulfide isomerase 1), SEC23 (secretory 23), TRX2 (thioredoxin 2) AHA1 (activator of heat shock protein 90 ATPase), and SCJ1 (S. cerevisiae DnaJ) followed by culturing the transformed yeast.
摘要翻译：本发明涉及一种大规模生产重组蛋白的方法，包括以下步骤：培养转化酵母的步骤：重组基因构建体，其包含酵母启动子，编码信号序列的基因和编码靶蛋白的基因; 以及选自PDI1（蛋白质二硫键异构酶1），SEC23（分泌型23），TRX2（硫氧还蛋白2））AHA1（热休克蛋白90 ATP酶的活化剂）和SCJ1（酿酒酵母DnaJ），然后培养转化的酵母。

14. 发明申请

US20100239657A1 COMPOSITE FOR LIVER-SPECIFIC DELIVERY AND RELEASE OF THERAPEUTIC NUCLEIC ACIDS OR DRUGS 有权
标题翻译：用于肝脏特异性递送和释放治疗性核酸或药物的复合材料
公开(公告)号：US20100239657A1
公开(公告)日：2010-09-23
申请号：US12791600
申请日：2010-06-01
申请人： Meehyein KIM , Soo In Kim , Duckhyang Shin , Mahnhoon Park
发明人： Meehyein KIM , Soo In Kim , Duckhyang Shin , Mahnhoon Park
IPC分类号： A61K9/127 , A61K31/711 , A61K31/7105 , A61K38/14 , A61K38/05 , A61K31/282 , A61K33/24 , A61K31/7048 , A61K31/704 , A61K31/513 , A61K31/505 , A61K31/44 , A61K31/722 , A61K31/7056 , A61K31/522 , A61K31/52 , A61K31/7072 , A61K31/496 , A61K31/215 , A61P31/18 , A61P31/20 , A61P35/00
CPC分类号： A61K31/7088 , A61K9/1272
摘要： The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
摘要翻译：具有纳米尺度粒度的本发明复合材料可以将治疗性核酸或药物特异性递送至肝脏并选择性地将它们释放到肝细胞中以显示出有效的治疗效果，而不引起任何酶促异常或对正常肝功能的病理损伤，当与治疗剂。

15. 发明申请

US20100196370A1 FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT 审中-公开
标题翻译：免疫球蛋白FC和人APOLIPOPROTEIN的融合蛋白（A）KRINGLE FRAGMENT
公开(公告)号：US20100196370A1
公开(公告)日：2010-08-05
申请号：US12519653
申请日：2007-11-16
申请人： Hyun-Kyung Yu , Yeup Yoon , Jin-Hyung Ahn , In-Hwan Lim , Ho-Jeong Lee , Jang-Seong Kim , Doo-Hong Park
发明人： Hyun-Kyung Yu , Yeup Yoon , Jin-Hyung Ahn , In-Hwan Lim , Ho-Jeong Lee , Jang-Seong Kim , Doo-Hong Park
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/06 , A61P35/04
CPC分类号： C07K14/775 , C07K2319/31
摘要： The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.
摘要翻译：本发明涉及具有增加的血管发生抑制活性和体内稳定性的LK8-Fc融合蛋白。更具体地，涉及其中具有血管生成抑制活性的LK8蛋白与人免疫球蛋白IgG1的Fc区融合的LK8-Fc融合蛋白以及含有融合蛋白的用于治疗癌症的组合物。 LK8-Fc融合蛋白不仅具有导致抗癌和转移抑制活性的血管发生抑制活性，而且具有非常长的体内半衰期，因此可用作更有效和经济的癌症治疗剂或癌症抑制剂。

16. 发明申请

US20100184136A1 Methods For Enhancing A Secretion Efficiency Of Recombinant Foreign Protein In Yeast Expression System 有权
标题翻译：用于增强酵母表达系统中重组外源蛋白的分泌效率的方法
公开(公告)号：US20100184136A1
公开(公告)日：2010-07-22
申请号：US12305768
申请日：2006-06-20
申请人： Hyung-Kwon Lim , Sung-Geun Kim
发明人： Hyung-Kwon Lim , Sung-Geun Kim
IPC分类号： C12P21/00
CPC分类号： C12N15/81
摘要： Provided is a method for improving secretion efficiency of a recombinant foreign protein in a yeast expression system. The method comprises transforming a yeast host with a recombinant foreign gene construct comprising a galactose-inducible promoter, a secretion signal sequence and a gene encoding the foreign protein to construct a transformed yeast strain; and culturing the transformed yeast strain under the condition that the activity of the galactose-inducible promoter is controlled. Improved secretion efficiency of the foreign protein can be achieved by decreasing over-expression-induced insoluble precipitation of the recombinant foreign protein suffered by a conventional galactose-inducible promoter-based yeast expression system, via appropriate control of a level of galactose functioning as an inducer of the galactose-inducible promoter in cells. Due to improved secretion efficiency of the recombinant foreign protein, present invention makes a contribution to improvement in productivity of recombinant foreign proteins in the yeast expression system and reduction in production costs.
摘要翻译：提供了一种用于提高酵母表达系统中重组外源蛋白的分泌效率的方法。该方法包括用包含半乳糖诱导型启动子，分泌信号序列和编码外源蛋白的基因的重组外源基因构建体来转化酵母宿主以构建转化的酵母菌株; 并在控制半乳糖诱导型启动子的活性的条件下培养转化的酵母菌株。通过适当控制用作诱导剂的半乳糖水平，通过减少由常规的基于半乳糖诱导型启动子的酵母表达系统所承受的重组外源蛋白质的过表达诱导的不溶性沉淀，可以实现外源蛋白质的分泌效率的提高。的半乳糖诱导型启动子。由于重组外源蛋白的分泌效率提高，本发明对于提高酵母表达系统中重组外源蛋白质的生产力和生产成本的降低有所贡献。

17. 发明申请

US20090162317A1 Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same 有权
标题翻译：编码能够结合各种HLA超型的HCV表位的多核苷酸，包含其的免疫原性组合物和使用其诱导HCV特异性免疫应答的方法
公开(公告)号：US20090162317A1
公开(公告)日：2009-06-25
申请号：US12289766
申请日：2008-11-03
申请人： Yu Kyeong Hwang , Okjae Lim , Hyejin Chung
发明人： Yu Kyeong Hwang , Okjae Lim , Hyejin Chung
IPC分类号： A61K38/20 , C12N15/11 , C12N15/00 , A61K35/12 , A61K39/29
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/5154 , A61K2039/5156 , A61K2039/53 , A61K2039/55516 , A61K2039/55527 , C12N2770/24222 , C12N2770/24234
摘要： There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.
摘要翻译：提供了编码HCV表位的多核苷酸，包含其的免疫原性组合物，以及使用它们诱导HCV特异性免疫应答的方法。

18. 发明申请

US20080200657A1 Mutant of Granulocyte-Colony Stimulating Factor (G-Csf) and Chemically Conjugated Polypeptide Thereof 有权
标题翻译：粒细胞集落刺激因子（G-Csf）和化学结合多肽的突变体
公开(公告)号：US20080200657A1
公开(公告)日：2008-08-21
申请号：US11995968
申请日：2006-07-19
申请人： Kwan-Yub Kang , Jeong-Woon Hong
发明人： Kwan-Yub Kang , Jeong-Woon Hong
IPC分类号： C07K14/435
CPC分类号： C07K14/535 , A61K47/60
摘要： Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (Gly) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity.
摘要翻译：提供设计用于特定化学共轭的人粒细胞集落刺激因子（G-CSF）的突变体，以及用作癌症治疗中的佐剂的化学共轭物。本发明提供了G-CSF的突变体，其中包含SEQ ID NO：1中鉴定的氨基酸序列的G-CSF的第133位的苏氨酸（Thr）残基被半胱氨酸（Cys）残基取代。此外，本发明提供了G-CSF的突变体，其中将半胱氨酸（Cys）残基插入在135位的甘氨酸（Gly）残基和G-CSF的第136位的丙氨酸（Ala）残基之间。此外，本发明提供了在半胱氨酸残基处连接生物相容性聚合物如聚乙二醇（PEG）的化学偶联的突变体G-CSF，其通过取代或插入突变引入，增加其体内保留时间而不降低体内由于与生物相容性聚合物共轭而产生的生物活性，从而最终延长了体内的生物活性。

19. 发明授权

US10066215B2 Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same 有权
公开(公告)号：US10066215B2
公开(公告)日：2018-09-04
申请号：US15279107
申请日：2016-09-28
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
发明人： Kyuhyun Lee , Seongtae Yun , Daekyung Koh , Hong-Kyu Lee , Eui-Cheol Jo
IPC分类号： C12N15/86 , C12N15/11 , C12N7/00 , C12N5/071 , A61K35/761 , C07K14/005 , A61K39/00
摘要： Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.

20. 发明申请

US20130259886A1 BROADLY PROTECTIVE INFLUENZA T-CELL VACCINE AGAINST DIVERSE INFLUENZA A VIRUSES 有权
标题翻译：广泛应用于流感病毒感染流行性感冒的T细胞疫苗
公开(公告)号：US20130259886A1
公开(公告)日：2013-10-03
申请号：US13666467
申请日：2012-11-01
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTIT
发明人： Jin-Won YOUN , Ji-Sun KWON , Jung-Soon YOON , Yeon-Jung KIM
IPC分类号： A61K39/145 , A61P37/04 , A61P31/16
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/57 , C12N2710/24143 , C12N2760/16134
摘要： There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses.
摘要翻译：提供了一种基于T细胞的通用流感疫苗，其包括能够针对广泛的异亚型流感病毒感染而制备的内部基因，从而准备不可预测的流行性感冒。本发明选择从鸟，猪和人流感病毒分离物获得的共有序列的内部基因，以开发基于T细胞的普遍流感疫苗。根据本发明的基于T细胞的普遍流感疫苗的特征在于包含至少一个CTL表位，通过含有多个内部基因并使用内部基因本身的整个序列。基于T细胞的普遍流感疫苗可以在感染异亚型流感病毒方面实现广泛的防御。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式